Focus: OrganOx is a UK-based biotechnology company specializing in organ transportation technology, with a focus on normothermic machine perfusion to improve liver transplantation outcomes. The company is publicly listed and currently hiring across 22 active roles, signaling active commercialization and expansion.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Growing — net +6 jobs in 30d
13 jobs added vs 7 removed. Steady team buildout.
OrganOx offers meaningful work in a revolutionary transplant technology space with near-term commercialization tailwinds, but early clinical stage and opaque financials carry execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for OrganOx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from OrganOx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Xenetic Biosciences, Inc. (XBIO) (CIK 0001534525) — PRESENTATION
PRESENTATION
New OrganOx Device Means Better Liver Transplants in the CU Anschutz Department of Surgery - University of Colorado Anschutz
New OrganOx Device Means Better Liver Transplants in the CU Anschutz Department of Surgery University of Colorado Anschutz
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Staged acellular perfusion, rewarming, and seamless transition to blood-based normothermic machine perfusion of the kidney: a paired porcine study.
Characterising prognostic complement biomarkers during clinical normothermic machine perfusion for renal transplantation.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo